REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

← catalyst calendar

NCT07594106 · readout in 1,530 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

265estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-20

actual

When the study began enrolling

Primary completion

2030-10-27

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-10-27

estimated

The whole study's end, after follow-up

First posted

2026-05-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-05

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

Drug: REGN15505
Drug: REGN15505+Cemiplimab — also filed as REGN2810, Libtayo
Drug: REGN15505+REGN4336

Primary outcomes

what the primary-completion date above is the date OF

Occurrence of Dose Limiting Toxicities (DLTs)

measured Up to 5 years

Occurrence of Treatment-Emergent Adverse Events (TEAEs)

measured Up to 5 years

Occurrence of Serious Adverse Events (SAEs)

measured Up to 5 years

Occurrence of Adverse Events of Special Interest (AESIs)

measured Up to 5 years

Composite Response (CompR) based on ≥50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic assessment of complete response (CR) or partial response (PR)

measured Up to 5 years

Objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

measured Up to 5 years

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed